产品编号 :
Cas No. :
CAS No. |
40077-57-4 |
|---|---|
中文名称 |
阿肽地尔 |
英文名称 |
- |
别名 |
VASOACTIVE INTESTINAL PEPTIDE (HUMAN, BOVINE, PORCINE, RAT);VASOACTIVE INTESTINAL PEPTIDE (HUMAN, PORCINE);VASOACTIVE INTESTINAL PEPTIDE, HUMAN, PORCINE, AND RAT;VASOACTIVE INTESTINAL PEPTIDE (HUMAN, PORCINE) (BOVINE, RAT, CANINE);VASOACTIVE INTESTINAL PEPTIDE HUMAN, PORCINE, RAT;VASOACTIVE INTESTINAL PEPTIDE, HUMAN, PORCINE, RAT, OVINE;VASOACTIVE INTESTINAL PEPTIDE, PORCINE;VASOACTIVE INTESTINAL PEPTIDE |
MDL No. |
MFCD00167535 |
分子式 |
C147H238N44O42S |
分子量 |
3325.85 |
精确分子量 |
3323.76 |
SMILES |
CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CN=CN1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(N)=O |
标准SMILES |
CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CN=CN1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(N)=O |
用途 |
Aviptadil is primarily used for the treatment of acute respiratory distress syndrome (ARDS) and idiopathic pulmonary fibrosis, demonstrating favorable efficacy and minimal side effects; it is also investigated for the treatment of pulmonary fibrosis, pulmonary arterial hypertension (PAH), and respiratory failure caused by SARS-CoV-2; additionally, it exhibits potent vasodilatory effects, inhibits proliferation of vascular smooth muscle cells (SMCs), suppresses platelet aggregation, and shows protective effects against cigarette smoke extract (CSE)-induced cell death and lipopolysaccharide (LPS)-induced MMP-9 activity in alveolar macrophages. |
InChIKey |
HEOYHMUESMJFDC-RIWXPGAOSA-N |
|
|
评论 |
|---|